CHINA PHARMA HOLDINGS, INC. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 14, 2012



Attached files
FileFilename
EXCEL - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R9.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R10.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R11.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - CHINA PHARMA HOLDINGS, INC.R13.htm
EX-32.1 - CHINA PHARMA HOLDINGS, INC.cphi10qex321033112.htm
EX-31.2 - CHINA PHARMA HOLDINGS, INC.cphi10qex312033112.htm
EX-32.2 - CHINA PHARMA HOLDINGS, INC.cphi10qex322033112.htm
EX-31.1 - CHINA PHARMA HOLDINGS, INC.cphi10qex311033112.htm
10-Q - CHINA PHARMA HOLDINGS, INC - CHINA PHARMA HOLDINGS, INC.cphi10q033112.htm
v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Cash Flows from Operating Activities:    
Net income $ 2,806,359 $ 5,103,622
Depreciation and amortization 365,223 441,993
Stock based compensation 56,489 41,898
Bad debt expense 320,098 9,428
Deferred income taxes (34,312) (1,414)
Derivative gain 0 (677,498)
Changes in assets and liabilities:    
Trade accounts receivable. (5,154,644) (1,464,957)
Other receivables. (20,247) (72,955)
Advances to suppliers. 944,949 794,570
Inventory. (2,619,634) (2,525,349)
Trade accounts payable. 2,725,945 (1,261,422)
Accrued expenses. 11,517 194,444
Accrued taxes payable. 443,684 184,552
Other payables. 54,337 44,932
Advances from customers. 219,942 574,632
Net Cash Provided by Operating Activities 119,706 1,386,476
Cash Flows from Investing Activities:    
Net investment in banker's acceptances 0 (467,902)
Advances for purchases of property and equipment and intangible assets (790,092) (843,378)
Purchase of property and equipment (7,926) (60,949)
Net Cash Used in Investing Activities (798,018) (1,372,229)
Cash Flows from Financing Activity:    
Proceeds from related party loan 0 67,919
Net Cash Provided by Financing Activity 0 67,919
Effect of Exchange Rate Changes on Cash (52,736) 34,393
Net Increase (Decrease) in Cash and Cash Equivalents (731,048) 111,559
Cash and Cash Equivalents at Beginning of Period 4,050,854 3,692,086
Cash and Cash Equivalents at End of Period 3,319,806 3,803,645
Supplemental Cash Flow Information:    
Cash paid for interest 75,567 58,170
Cash paid for income taxes 274,587 385,546
Supplemental Noncash Investing and Financing Activities:    
Accounts payable for purchases of property and equipment 144,057 143,839
Accounts receivable collected with banker's acceptances 1,420,102 0
Inventory purchased with banker's acceptances $ 1,138,429 $ 0

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by CHINA PHARMA HOLDINGS, INC. and has no official or unofficial affiliation with CHINA PHARMA HOLDINGS, INC.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.